LGVN ▼ -2.6% - Longeveron Inc. $LGVN LGVNR - Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) Longeveron shares fell 2.6% following the company's announcement of topline results from its ELPIS II Phase 2b trial of laromestrocel for hypoplastic left heart syndrome. The decline suggests the market's initial interpretation of the trial results was negative or disappointing relative to investor expectations, though the specific efficacy or safety data would determine whether the outcome met or missed primary endpoints. 16-SEP-2026 05:27 PM ET